CJC-1295 + Ipamorelin + Tesamorelin Research Set
Explore the CJC-1295 + Ipamorelin + Tesamorelin Research Set at Glow peptide. This research set brings together three distinct compounds discussed in peptide and endocrine research: CJC-1295, Ipamorelin and Tesamorelin. Each has a different molecular structure and scientific research background.
What Is Included in This Research Set?
The set contains three research compounds:
- CJC-1295: A synthetic growth hormone-releasing hormone (GHRH) analogue investigated in research involving growth hormone signalling.
- Ipamorelin: A synthetic peptide investigated for its activity at the ghrelin receptor, also known as the growth hormone secretagogue receptor.
- Tesamorelin: A synthetic GHRH analogue studied in relation to growth hormone regulation and endocrine processes.
Understanding the Three Research Components
1. CJC-1295
CJC-1295 is a synthetic peptide analogue of growth hormone-releasing hormone. Scientific research has examined its relationship to growth hormone secretion and endocrine signalling.
Different CJC-1295 formulations, including versions with and without DAC, should not automatically be treated as interchangeable. The exact formulation should be confirmed from the product documentation.
Explore our CJC-1295 and Ipamorelin product information for additional details about the related compounds.
2. Ipamorelin
Ipamorelin is a synthetic peptide studied for its interaction with the ghrelin receptor, also known as GHS-R1a. Research has investigated its relationship to growth hormone secretion and related endocrine signalling pathways.
Its molecular characteristics and receptor activity distinguish it from GHRH analogues such as CJC-1295 and Tesamorelin.
Learn more through our CJC-1295 + Ipamorelin product page.
3. Tesamorelin
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone. It has been studied in endocrine research involving growth hormone regulation.
Tesamorelin also has a specific FDA-approved prescription formulation and indication for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. This approval applies to the regulated prescription medicine and its labelled indication; it does not establish approval or effectiveness for this research set or other uses.
Explore our Tesamorelin product information for additional background.
Why Study These Three Compounds Separately?
CJC-1295, Ipamorelin and Tesamorelin are related to growth hormone signalling, but they do not have identical molecular structures or mechanisms of action.
CJC-1295 and Tesamorelin are GHRH analogues, whereas Ipamorelin is a ghrelin receptor agonist. Understanding these differences helps distinguish their individual research profiles.
Scientific findings involving one compound do not establish the safety, compatibility or effectiveness of combining all three. The research evidence for each substance must be evaluated independently.
Scientific Research and Further Reading
For additional scientific background, consult these biomedical research resources:
- CJC-1295 scientific publications
- Ipamorelin scientific publications
- Tesamorelin scientific publications
- FDA Drugs@FDA database for information on approved prescription products and their indications.
Explore More Research Products
Discover additional products in our research bundles collection or browse the complete Glow Peptide product catalogue.
Frequently Asked Questions
What is included in the CJC-1295 + Ipamorelin + Tesamorelin Research Set?
The set contains three components: CJC-1295, Ipamorelin and Tesamorelin.
What is CJC-1295?
CJC-1295 is a synthetic GHRH analogue investigated in research involving growth hormone signalling and endocrine biology.
What is Ipamorelin?
Ipamorelin is a synthetic peptide investigated for its interaction with the ghrelin receptor and its relationship to growth hormone secretion.
What is Tesamorelin?
Tesamorelin is a synthetic GHRH analogue studied in endocrine research. A specific prescription formulation is FDA-approved for a defined indication involving HIV-associated lipodystrophy.
Are CJC-1295 and Tesamorelin the same?
No. Although both are GHRH analogues, they are different compounds with distinct molecular structures and research histories.
Are these three compounds the same type of peptide?
They are all peptide-based compounds, but they have different molecular structures and biological activities. Ipamorelin acts through the ghrelin receptor, while CJC-1295 and Tesamorelin are GHRH analogues.
Does combining these compounds establish additional benefits?
No. Evidence involving individual compounds does not establish the safety, compatibility or effectiveness of their combination. The combined research set requires its own scientific evaluation.
Where can I find more information about the individual components?
Visit our CJC-1295 + Ipamorelin and Tesamorelin product pages for further information.
Research Information Notice
This product information is provided for educational and research-reference purposes only. It is not medical advice and does not establish that the individual compounds or combined research set are approved, safe or effective for human use. FDA approval of a specific Tesamorelin prescription formulation does not extend to this research set. No personal-use, administration or dosing instructions are provided.




Reviews
There are no reviews yet.